Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 5/20 | 0.61 |
| ▸ | VIPR2 | P41587 | 7/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.60 |
| ▸ | GLP1R | P43220 | 4/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.58 |
| ▸ | TFPI | P10646 | 3/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histatin 3 SCHEMBL29445556 | 0.94 | VIPR1 (0.69) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL29366375 | 0.93 | VIPR2 (0.64) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL29581965 | 0.92 | VIPR1 (0.55) | VIPR1VIPR2CXCR4GLP1RECE1 | |
| Histatin 5 SCHEMBL31694496 | 0.89 | GLP1R (0.57) | GLP1RTFPI | |
| SCHEMBL29679886 | 0.87 | NPY5R (0.56) | TFPI | |
| SCHEMBL29405667 | 0.86 | TFPI (0.66) | TFPI | |
| SCHEMBL29610203 | 0.85 | VIPR1 (0.65) | VIPR1VIPR2 | |
| SCHEMBL30900782 | 0.84 | TFPI (0.65) | TFPIOPRL1 | |
| SCHEMBL30900790 | 0.84 | TFPI (0.65) | TFPIOPRL1 | |
| Histatin 3 SCHEMBL31694493 | 0.84 | TFPI (0.63) | VIPR1VIPR2GLP1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061092-A1 | MINERALIZATION OF CELL-LADEN MATRICES | UNIV OREGON HEALTH & SCIENCE (US) | 2026-03-05 | — | — | US | claimed |
| EP-4677099-A2 | HERBICIDE-RESISTANT GENES FOR MITOCHONDRIAL TRANSFORMATION | Napigen, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4626496-A1 | BIOPROSTHETIC TISSUE AND PROSTHETIC ANTIMICROBIAL TREATMENT | Edwards Lifesciences Corporation (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250296961-A1 | ANTIMICROBIAL PEPTIDES FOR REMINERALIZATION OF TEETH AND PREVENTION OF DENTAL CARIES | THE UNIVERSITY OF HONG KONG (CN) | 2025-09-25 | — | — | US | claimed |
| US-20250275905-A1 | ANTIBACTERIAL AND MINERALIZING COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2025-09-04 | — | — | US | claimed |
| CN-119867265-A | Tenderness agent for improving tenderness of stewed meat and use method thereof | 河北农业大学 | 2025-04-25 | — | — | CN | claimed |
| US-20250027099-A1 | PHOSPHITE DEHYDROGENASE AS A SELECTABLE MARKER FOR MITOCHONDRIAL TRANSFORMATION | NAPIGEN, INC. | 2025-01-23 | — | — | US | claimed |
| WO-2024187111-A2 | HERBICIDE-RESISTANT GENES FOR MITOCHONDRIAL TRANSFORMATION | NAPIGEN, INC. (US) | 2024-09-12 | — | — | WO | claimed |
| EP-4380579-A1 | MIRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF | Leadermed Champion Limited (CN) | 2024-06-12 | — | — | EP | claimed |
| WO-2024118297-A1 | BIOPROSTHETIC TISSUE AND PROSTHETIC ANTIMICROBIAL TREATMENT | EDWARDS LIFESCIENCES CORPORATION (US) | 2024-06-06 | — | — | WO | claimed |
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | claimed |
| WO-2022174715-A1 | ANTIBACTERIAL AND MINERALIZING COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2022-08-25 | — | — | WO | claimed |
| WO-2022173893-A1 | USE OF HISTIDINE RICH PEPTIDES AS A TRANSFECTION REAGENT FOR rAAV AND rBV PRODUCTION | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-08-18 | — | — | WO | claimed |
| WO-2022174142-A1 | COMPOSITIONS AND METHODS FOR USING COMBINATIONS OF ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS | Virongy L.L.C. (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220257593-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | VISUS THERAPEUTICS, INC. | 2022-08-18 | — | — | US | claimed |
| US-20220238042-A1 | ENGINEERED BONE MARROW MODEL | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-07-28 | — | — | US | claimed |
| CN-114502155-A | Carbachol-brimonidine formulations for enhanced anti-presbyopia | 视觉治疗股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3980005-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | Visus Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| EP-3966312-A1 | ENGINEERED BONE MARROW MODEL | Oregon Health & Science University (US) | 2022-03-16 | — | — | EP | claimed |
| CN-114106937-A | Contact lens care solution | 东南大学 | 2022-03-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061092-A1 | MINERALIZATION OF CELL-LADEN MATRICES | COL2A1, FIBP, COL1A1 | VIPR1 2873/4885VIPR2 2947/4885CXCR4 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.